Comparing validated hepatocellular carcinoma risk scores for chronic hepatitis B against current Australian surveillance guidelines

doi:10.4254/wjh.117996

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(23)

(20)

(0)

(13)

(212)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Jun 27, 2026; 18(6): 117996
Published online Jun 27, 2026. doi: 10.4254/wjh.117996

Table 5 Baseline characteristics of the study population, n (%)/mean ± SD

Characteristics
Demographics	Total (n)	314
	Age	50.6 ± 13.1
	Male sex	110 (35.0)
Continent of origin	Asia	219 (69.7)
	Oceania	63 (20.0)
	Europe	17 (5.4)
	Africa	10 (3.2)
	Unknown	5 (1.6)
Clinical	LSM (kPa)	5.3 ± 1.8
	Current antiviral use	119 (37.9)
	Diabetes	16 (5.1)
	Excess alcohol use	38 (12.1)
	1^st degree family history HCC	20 (6.7)
	2^nd degree family history HCC	13 (4.1)
Biochemical	ALT (U/L)	45 ± 196.3
	Platelet count (× 10⁹/L)	240.9 ± 64.3
	AFP (μg/L)	4.3 ± 21.3
	HBeAg positive	30 (9.6)
	HBV DNA < 2000 IU/mL	188 (59.9)
HCC development	Progression to HCC	2 (0.63)

HCC: Hepatocellular carcinoma; LSM: Liver stiffness measurement; HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase; AFP: Alpha foetoprotein; HBV: Hepatitis B virus.

Full Size Table

Citation: Mian I, Subhaharan D, Haig A, Cox R, Masood T, Braund A, Funakoshi N. Comparing validated hepatocellular carcinoma risk scores for chronic hepatitis B against current Australian surveillance guidelines. World J Hepatol 2026; 18(6): 117996
URL: https://www.wjgnet.com/1948-5182/full/v18/i6/117996.htm
DOI: https://dx.doi.org/10.4254/wjh.117996

Mian I, Subhaharan D, Haig A, Cox R, Masood T, Braund A, Funakoshi N. Comparing validated hepatocellular carcinoma risk scores for chronic hepatitis B against current Australian surveillance guidelines. World J Hepatol 2026; 18(6): 117996 [DOI: 10.4254/wjh.117996]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.